头孢曲松在预测肠杆菌科分离株对口服高级别头孢菌素的敏感性方面有多准确？
How accurate is ceftriaxone at predicting susceptibility of enterobacterales isolates to oral higher-generation cephalosporins?
作者信息
Claeys Kimberly C, Simner Patricia J, Tekle Tsigereda, Harris Anthony D, Jacobs Emily, Cosgrove Sara E, Tamma Pranita D
机构信息
Department of Pharmacy Science and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0138724. doi: 10.1128/aac.01387-24. Epub 2024 Dec 31.
Abstract
The reliability of ceftriaxone for inferring susceptibility to higher-generation oral cephalosporins is unknown. Overall, ceftriaxone susceptibility predicted susceptibility to cefuroxime (89%), cefdinir (86%), cefpodoxime (90%), and cefixime (94%) based on disk diffusion results for 409 consecutive Enterobacterales bloodstream isolates from unique patients. Susceptibility percentages to the four oral cephalosporins ranged from 92% to 99% when limited to , isolates susceptible to ceftriaxone.
摘要
头孢曲松用于推断对更高代口服头孢菌素敏感性的可靠性尚不清楚。总体而言，根据对409例来自不同患者的连续肠杆菌科血流分离株的纸片扩散结果，头孢曲松敏感性预测了对头孢呋辛（89%）、头孢地尼（86%）、头孢泊肟（90%）和头孢克肟（94%）的敏感性。当仅限于对头孢曲松敏感的分离株时，对四种口服头孢菌素的敏感率在92%至99%之间。
相似文献
1
How accurate is ceftriaxone at predicting susceptibility of enterobacterales isolates to oral higher-generation cephalosporins?头孢曲松在预测肠杆菌科分离株对口服高级别头孢菌素的敏感性方面有多准确？
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0138724. doi: 10.1128/aac.01387-24. Epub 2024 Dec 31.
2
Surrogate testing of oral third-generation cephalosporin susceptibility to common uropathogens.常见尿路病原体的第三代口服头孢菌素药敏性的替代检测。
Diagn Microbiol Infect Dis. 2021 Apr;99(4):115299. doi: 10.1016/j.diagmicrobio.2020.115299. Epub 2021 Jan 15.
3
Re-evaluation of penicillin and ceftriaxone MIC results to predict susceptibility to the oral cephalosporin, cefpodoxime, in clinical isolates from the United States according to CLSI guidelines (2019-2021).根据美国临床和实验室标准协会（CLSI）指南（2019 - 2021年）重新评估青霉素和头孢曲松的最低抑菌浓度（MIC）结果，以预测美国临床分离株对口服头孢菌素头孢泊肟的敏感性。
J Clin Microbiol. 2025 Jun 24:e0002725. doi: 10.1128/jcm.00027-25.
4
Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.头孢泊肟与头孢克肟、头孢地尼、头孢他美、头孢布烯、氯碳头孢、头孢丙烯、BAY 3522、头孢呋辛、头孢克洛和头孢羟氨苄的抗菌活性比较。
Infection. 1991 Sep-Oct;19(5):353-62. doi: 10.1007/BF01645369.
5
Evaluation of cefazolin as a surrogate marker for cefpodoxime susceptibility for urinary tract isolates.评估头孢唑林作为尿路分离株头孢泊肟敏感性替代标志物的作用。
J Med Microbiol. 2015 Oct;64(10):1170-1173. doi: 10.1099/jmm.0.000142. Epub 2015 Jul 23.
6
Molecular epidemiology of β-lactamases in ceftriaxone-resistant Enterobacterales bloodstream infections in the mid-Atlantic United States.美国中大西洋地区耐头孢曲松肠杆菌血流感染中β-内酰胺酶的分子流行病学
Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0125824. doi: 10.1128/aac.01258-24. Epub 2025 Jan 27.
7
In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial.MERINO 试验中口服第三代头孢菌素加克拉维酸对产 ESBL 肠杆菌科分离株的体外活性。
Int J Antimicrob Agents. 2023 Aug;62(2):106858. doi: 10.1016/j.ijantimicag.2023.106858. Epub 2023 May 19.
8
Clinical outcomes of phenotype-guided treatment in group D carbapenemase-producing bacteremia.产D组碳青霉烯酶菌血症中表型导向治疗的临床结局
Microbiol Spectr. 2025 Jul;13(7):e0027325. doi: 10.1128/spectrum.00273-25. Epub 2025 May 27.
9
Influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae.青霉素/阿莫西林不敏感性对第三代头孢菌素抗肺炎链球菌活性的影响。
Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):75-80. doi: 10.1007/s10096-007-0402-5. Epub 2007 Oct 18.
10
Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis.全球淋病奈瑟菌分离株对头孢克肟和头孢泊肟的敏感性：系统评价和荟萃分析。
PLoS One. 2014 Jan 31;9(1):e87849. doi: 10.1371/journal.pone.0087849. eCollection 2014.
引用本文的文献
1
Navigating the Muddled Middle: A Case-Based Exploration of Oral β-Lactams for Systemic Gram-Negative Infections.探索复杂的中间地带：基于病例探讨口服β-内酰胺类药物治疗全身性革兰氏阴性菌感染
Open Forum Infect Dis. 2025 Sep 3;12(9):ofaf435. doi: 10.1093/ofid/ofaf435. eCollection 2025 Sep.
本文引用的文献
1
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.美国传染病学会2024年抗微生物药物耐药革兰氏阴性菌感染治疗指南
Clin Infect Dis. 2024 Aug 7. doi: 10.1093/cid/ciae403.
2
Ceftriaxone Versus Cefazolin Susceptibility as a Surrogate Marker for Cefpodoxime Susceptibility in Enterobacterales.头孢曲松与头孢唑林敏感性作为肠杆菌科细菌中头孢泊肟敏感性替代标志物的研究
Open Forum Infect Dis. 2024 Jul 3;11(7):ofae377. doi: 10.1093/ofid/ofae377. eCollection 2024 Jul.
3
Early Switch From Intravenous to Oral Antibiotics for Patients With Uncomplicated Gram-Negative Bacteremia.早期将静脉内抗生素转换为口服抗生素治疗无并发症革兰氏阴性菌血症患者。
JAMA Netw Open. 2024 Jan 2;7(1):e2352314. doi: 10.1001/jamanetworkopen.2023.52314.
4
Transition to Oral Antibiotic Therapy for Hospitalized Adults With Gram-Negative Bloodstream Infections.革兰氏阴性菌血流感染住院成人患者的口服抗生素治疗转换。
JAMA Netw Open. 2024 Jan 2;7(1):e2349864. doi: 10.1001/jamanetworkopen.2023.49864.
5
Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?碳青霉烯类治疗是否有必要用于治疗非 CTX-M 型超广谱β-内酰胺酶产生肠杆菌血流感染？
Clin Infect Dis. 2024 May 15;78(5):1103-1110. doi: 10.1093/cid/ciad703.
6
Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process.优化非复杂性革兰阴性菌血流感染的管理：采用改良德尔菲法的共识指南
Open Forum Infect Dis. 2021 Oct 11;8(10):ofab434. doi: 10.1093/ofid/ofab434. eCollection 2021 Oct.
7
Variability in oral antibiotic step-down therapy in the management of Gram-negative bloodstream infections.革兰氏阴性菌血流感染管理中口服降阶梯抗生素治疗的变异性。
Int J Antimicrob Agents. 2021 Dec;58(6):106451. doi: 10.1016/j.ijantimicag.2021.106451. Epub 2021 Oct 20.
8
Clinical considerations for oral beta-lactams as step-down therapy for Enterobacteriaceae bloodstream infections.口服β-内酰胺类药物作为肠杆菌科血流感染降阶梯治疗的临床考量
Expert Opin Pharmacother. 2019 Jun;20(8):903-907. doi: 10.1080/14656566.2019.1594774. Epub 2019 Mar 25.
9
A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World.AmpC β-内酰胺酶入门：应对日益增多的多重耐药问题的必备知识
Clin Infect Dis. 2019 Sep 27;69(8):1446-1455. doi: 10.1093/cid/ciz173.
10
Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.肠杆菌科菌血症住院患者口服降阶梯治疗与持续静脉内治疗与 30 天死亡率的关联。
JAMA Intern Med. 2019 Mar 1;179(3):316-323. doi: 10.1001/jamainternmed.2018.6226.
Zotero 插件